2020. Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s108. DOI:https://doi.org/10.25251/skin.4.supp.108.